Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization

World Journal of Gastroenterology

Volumn 20, Issue 43, 2014, Pages 15975-15991

  Vercauteren, Koen ^a   Mesalam, Ahmed Atef ^a   Leroux Roels, Geert ^a   Meuleman, Philip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Animal models; Antiviral therapy; Hepatitis; Lipids; Neutralisation

Indexed keywords

APOLIPOPROTEIN; FAT DROPLET; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NEUTRALIZING ANTIBODY; VERY LOW DENSITY LIPOPROTEIN; VIRUS ENVELOPE PROTEIN; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY;

ANTIVIRAL THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER CELL; LIVER TRANSPLANTATION; NONHUMAN; REVIEW; RNA REPLICATION; SECRETORY PATHWAY; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ADVERSE EFFECTS; ANIMAL; BLOOD; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIVER; METABOLISM; PATHOGENICITY; TREATMENT OUTCOME; VIROLOGY; VIRULENCE; VIRUS ACTIVATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIPIDS; LIPOPROTEINS; LIVER; LIVER TRANSPLANTATION; TREATMENT OUTCOME; VIRULENCE; VIRUS ACTIVATION; VIRUS INTERNALIZATION;

EID: 84912557392     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i43.15975     Document Type: Review

References (169)

1. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 610-622 [PMID: 18838975 DOI: 10.1038/ncpgasthep1274].
2. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 Suppl 1: S88-S100 [PMID: 22300469 DOI: 10.1016/S0168-8278(12)60010-5].
3. Manns M, Marcellin P, Poordad FPF, de Araujo ESA, Buti M, Horsmans Y, Janczewska EJE, Villamil F, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. Simeprevir (Tmc435) with Peginterferon/Ribavirin for Treatment of Chronic Hcv Genotype-1 Infection in Treatment- Naive Patients: Results from Quest-2, a Phase Iii Trial. J Hepatol 2013; 58: S568-S568.
4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853].
5. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10 [PMID: 19902246 DOI: 10.1007/s00430-009-0131-8].
6. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents- A potentially lethal cocktail. Hepatology 2011; 54: 3-5 [PMID: 21710471 DOI: 10.1002/hep.24470].
7. Curry MP, Forns X, Chung RT, Terrault N, Brown RS, Fenkel JM, Gordon FD, O'Leary JG, Kuo A, Schiano TD, Everson GT, Schiff ER, Befeler A, McHutchison JG, Symonds WT, Denning JM, McNair L, Arterburn S, Moonka D, Gane EJ, Afdhal NH. Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation. Hepatology 2013; 58: 314a-315a.
8. Charlton MR, Gane EJ, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman LW, Muir AJ, McHutchison JG, Symonds WT, Denning JM, McNair L, Arterburn S, Terrault N, Samuel D, Forns X. Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study. Hepatology 2013; 58: 1378a-1378a.
9. Forns X, Fontana RJ, Moonka D, McHutchison JG, Symonds WT, Denning JM, McNair L, Chang P, Kivett VA, Shiffman ML, Charlton MR. Initial Evaluation of the Sofosbuvir Compassionate Use Program for Patients with Severe Recurrent HCV Following Liver Transplantation. Hepatology 2013; 58: 732a-733a.
10. Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown R, Gordon F, Levitsky J, Terrault N, Burton J, Xie W, Setze C, Badri P, Vilchez R, Forns X. Results of the phase 2 study M12-999: Interferon-free regimen of ABT-450/r/ABT-267 ABT-333 ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. J Hepatol 2014; 60: S47-s48 [DOI: 10.1016/S0168-8278(14)60116-1].
11. Vercauteren K, Leroux-Roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. Future Virol 2012; 7: 547-561 [DOI: 10.2217/Fvl.12.47].
12. Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: The role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 2008; 317: 1-38 [PMID: 17990788 DOI: 10.1007/978-3-540-721 46-8-1].
13. Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001; 99: 320-324 [PMID: 11358426 DOI: 10.1006/clim.2001.5036].
14. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104: 6025-6030 [PMID: 17392433 DOI: 10.1073/pnas.0607026104].
15. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394-15399 [PMID: 8986822 DOI: 10.1073/pnas.93.26.15394].
16. Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH, Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 2008; 47: 1846-1855 [PMID: 18452146 DOI: 10.1002/hep.22244].
17. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011; 53: 755-762 [PMID: 21319203 DOI: 10.1002/hep.24171].
18. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012; 8: e1002895 [PMID: 22952447 DOI: 10.1371/journal.ppat.1002895].
19. Willems B, Ede M, Marotta P, Wall W, Greig P, Lilly L, Kneteman N, Wong WN, Roy A, Marleau D, Scudamore C, Yoshida E, Rinfret A. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J Hepatol 2002; 36: 32-32 [DOI: 10.1016/S0168-8278(02)80095-2].
20. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Gnann JW. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-949 [PMID: 16035063 DOI: 10.1002/lt.20405].
21. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, Eren R, Dagan S, Graham N, Williams PV, Andrews J. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006; 12: 1381-1389 [PMID: 16933235 DOI: 10.1002/lt.20876].
22. Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, Florman S, Schilsky M, Broering TJ, Finberg RW, Szabo G, Zamore PD, Khettry U, Babcock GJ, Ambrosino DM, Leav B, Leney M, Smith HL, Molrine DC. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study. Am J Transplant 2013; 13: 1047-1054 [PMID: 23356386 DOI: 10.1111/ajt.12083].
23. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79: 8217-8229 [PMID: 15956567 DOI: 10.1128/JVI.79.13.8217-8229.2005].
24. Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 2006; 87: 2577-2581 [PMID: 16894196 DOI: 10.1099/vir.0.81932-0].
25. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79: 6023-6034 [PMID: 15857988 DOI: 10.1128/JVI.79.10.6023-6034.2005].
26. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-41012 [PMID: 12867431 DOI: 10.1074/jbc.M302267200].
27. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771 [PMID: 10535997 DOI: 10.1073/pnas.96.22.12766].
28. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941 [PMID: 9794763 DOI: 10.1126/science.282.5390.938].
29. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718 DOI: 10.1093/emboj/cdf529].
30. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805 [PMID: 17325668 DOI: 10.1038/nature05654].
31. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886 [PMID: 19182773 DOI: 10.1038/nature07684].
32. Griffin BA. Lipid metabolism. Surgery (Oxford) 2013; 31: 267-272 [DOI: 10.1016/j.mpsur.2013.04.006].
33. Chappell DA, Medh JD. Receptor-mediated mechanisms of lipoprotein remnant catabolism. Prog Lipid Res 1998; 37: 393-422 [PMID: 10209655].
34. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: Structure, function, regulation, and role in disease. J Mol Med (Berl) 2002; 80: 753-769 [PMID: 12483461 DOI: 10.1007/s00109-002-0384-9].
35. Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905-1919 [PMID: 22508840 DOI: 10.1161/CIRCULATIONAHA. 111.066589].
36. Brown WV. High-density lipoprotein and transport of cholesterol and triglyceride in blood. J Clin Lipidol 2007; 1: 7-19 [PMID: 21291664 DOI: 10.1016/j.jacl.2007.02.001].
37. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-434 [PMID: 11322205].
38. Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13: 56-61 [PMID: 16364083 DOI: 10.1111/j.1365-2893.2005.00655.x].
39. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267].
40. Walters KA, Joyce MA, Thompson JC, Smith MW, Yeh MM, Proll S, Zhu LF, Gao TJ, Kneteman NM, Tyrrell DL, Katze MG. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog 2006; 2: e59 [PMID: 16789836 DOI: 10.1371/journal.ppat.0020059].
41. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 15669-15674 [PMID: 12441396 DOI: 10.1073/pnas.202608199].
42. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC, Min AD. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-340 [PMID: 16871569 DOI: 10.1002/hep.21261].
43. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-125 [PMID: 16799963 DOI: 10.1002/hep.21232].
44. Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16 [PMID: 19437494 DOI: 10.1002/hep.22916].
45. Milazzo L, Meroni L, Galazzi M, Cesari M, Caramma I, Marchetti G, Galli M, Antinori S. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 2009; 16: 479-484 [PMID: 19215577 DOI: 10.1111/j.1365-2893.2009.01104.x].
46. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial. Hepatology 2007; 45: 895-898 [PMID: 17393518 DOI: 10.1002/hep.21554].
47. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103: 1383-1389 [PMID: 18410471 DOI: 10.1111/j.1572-0241.2008.01876.x].
48. Forde KA, Law C, O'Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009; 15: 5020-5027 [PMID: 19859994].
49. Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 coinfected patients: An open-label randomized controlled study. J Antimicrob Chemother 2010; 65: 735-740 [PMID: 20118492 DOI: 10.1093/jac/dkq002].
50. Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol 2013; 28: 51-56 [PMID: 22989264 DOI: 10.1111/j.1440-1746.2012.07267.x].
51. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-874 [PMID: 20568303 DOI: 10.1002/hep.23787].
52. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011; 140: 144-152 [PMID: 20833169 DOI: 10.1053/j.gastro.2010.08.055].
53. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, Konishi M, Iwasa M, Watanabe S, Adachi Y. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006; 13: 441-448 [PMID: 16792537 DOI: 10.1111/j.1365-2893.2005.00718. x].
54. Dai CY, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study. J Hepatol 2008; 49: 9-16 [PMID: 18486265 DOI: 10.1016/j.jhep.2008.03.016].
55. Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56: 1105-1110 [PMID: 16956918 DOI: 10.1136/gut.2006.091983].
56. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-7080 [PMID: 17131467].
57. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708 [PMID: 19845037 DOI: 10.1002/hep.23206].
58. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-454 [PMID: 19919569 DOI: 10.1111/j.1478-3231.2009.02171.x].
59. Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103 [PMID: 21146993 DOI: 10.1016/j.tim.2010.11.005].
60. Andrè P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V. Characterization of low- And very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-6928 [PMID: 12072493].
61. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-2428 [PMID: 16474148 DOI: 10.1128/Jvi.80.5.2418-2428.2006].
62. Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, Trépo C, Lotteau V, André P. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006; 87: 2983-2991 [PMID: 16963757 DOI: 10.1099/vir.0.82033-0].
63. Rhainds D, Brissette L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int J Biochem Cell Biol 2004; 36: 39-77 [PMID: 14592533].
64. Rigotti A, Miettinen HE, Krieger M. The role of the highdensity lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24: 357-387 [PMID: 12788804].
65. Röhrl C, Stangl H. HDL endocytosis and resecretion. Biochim Biophys Acta 2013; 1831: 1626-1633 [PMID: 23939397 DOI: 10.1016/j.bbalip.2013.07.014].
66. Dao Thi VL, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 2012; 287: 31242-31257 [PMID: 22767607 DOI: 10.1074/jbc.M112.365924].
67. Maillard P, Huby T, Andréo U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoBcontaining lipoproteins. FASEB J 2006; 20: 735-737 [PMID: 16476701 DOI: 10.1096/fj.05-4728fje].
68. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007; 46: 1722-1731 [PMID: 18000990 DOI: 10.1002/hep.21994].
69. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. High- Avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81: 8063-8071 [PMID: 17507483 DOI: 10.1128/JVI.00193-07].
70. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. A human monoclonal an-tibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55: 364-372 [PMID: 21953761 DOI: 10.1002/hep.24692].
71. Nieland TJ, Penman M, Dori L, Krieger M, Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci USA 2002; 99: 15422-15427 [PMID: 12438696 DOI: 10.1073/pnas.222421399].
72. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280: 7793-7799 [PMID: 15632171 DOI: 10.1074/jbc.M411600200].
73. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281: 18285-18295 [PMID: 16675450 DOI: 10.1074/jbc.M602706200].
74. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011; 85: 596-605 [PMID: 20962076 DOI: 10.1128/JVI.01592-10].
75. Mittapalli GK, Jackson A, Zhao F, Lee H, Chow S, McKelvy J, Wong-Staal F, Macdonald JE. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. Bioorg Med Chem Lett 2011; 21: 6852-6855 [PMID: 21978675 DOI: 10.1016/j.bmcl.2011.09.019].
76. Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54: 48-55 [PMID: 20932595 DOI: 10.1016/j.jhep.2010.06.024].
77. Zahid MN, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2013; 57: 492-504 [PMID: 23081796 DOI: 10.1002/hep.26097].
78. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010; 84: 34-43 [PMID: 19828610 DOI: 10.1128/JVI.02199-08].
79. Guo L, Chen M, Song Z, Daugherty A, Li XA. C323 of SR-BI is required for SR-BI-mediated HDL binding and cholesteryl ester uptake. J Lipid Res 2011; 52: 2272-2278 [PMID: 21917726 DOI: 10.1194/jlr.M019091].
80. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-438 [PMID: 19299327 DOI: 10.1161/ATVBAHA.108.179564].
81. Wünschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74: 10055-10062 [PMID: 11024134].
82. Monazahian M, Böhme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57: 223-229 [PMID: 10022791].
83. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, Roitelman J, Barbaras R, Graber P, Ghersa P, Smolarsky M, Funaro A, Malavasi F, Larrey D, Coste J, Fabre JM, Sa-Cunha A, Maurel P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46: 411-419 [PMID: 17156886 DOI: 10.1016/j.jhep.2006.09.024].
84. Owen DM, Huang H, Ye J, Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108 [PMID: 19751943 DOI: 10.1016/j.virol.2009.08.037].
85. Mazumdar B, Banerjee A, Meyer K, Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 2011; 54: 1149-1156 [PMID: 21735466 DOI: 10.1002/hep.24523].
86. Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol 2010; 84: 12048-12057 [PMID: 20826689 DOI: 10.1128/JVI.01063-10].
87. Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. J Virol 2014; 88: 1725-1739 [PMID: 24257605 DOI: 10.1128/JVI.02017-13].
88. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Tercé F, Duverlie G, Rouillé Y, Dubuisson J. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012; 55: 998-1007 [PMID: 22121002 DOI: 10.1002/hep.25501].
89. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581].
90. Yu L. The structure and function of Niemann-Pick C1-like 1 protein. Curr Opin Lipidol 2008; 19: 263-269 [PMID: 18460917 DOI: 10.1097/MOL.0b013e3282f9b563].
91. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204 [PMID: 14976318].
92. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann- Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007; 117: 1968-1978 [PMID: 17571164 DOI: 10.1172/JCI30060].
93. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008; 6: 447-470 [PMID: 18402536 DOI: 10.1586/14 779072.6.4.447].
94. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68: 206-215 [PMID: 12210409 DOI: 10.1002/jmv.10196].
95. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. Viral and cellular determinants of the hepatitis C virus envelopeheparan sulfate interaction. J Virol 2006; 80: 10579-10590 [PMID: 16928753 DOI: 10.1128/JVI.00941-06].
96. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308-5320 [PMID: 16699011 DOI: 10.1128/JVI.02460-05].
97. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012; 86: 7256-7267 [PMID: 22532692 DOI: 10.1128/JVI.07222-11].
98. Shi Q, Jiang J, Luo G. Syndecan-1 serves as the major recep-tor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 2013; 87: 6866-6875 [PMID: 23576506 DOI: 10.1128/JVI.03475-12].
99. Heeren J, Niemeier A, Merkel M, Beisiegel U. Endothelialderived lipoprotein lipase is bound to postprandial triglyceride- rich lipoproteins and mediates their hepatic clearance in vivo. J Mol Med (Berl) 2002; 80: 576-584 [PMID: 12226739 DOI: 10.1007/s00109-002-0351-5].
100. Zheng C, Murdoch SJ, Brunzell JD, Sacks FM. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006; 26: 891-896 [PMID: 16410459 DOI: 10.1161/01.ATV.0000203512.01007.3d].
101. Andréo U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P, Budkowska A. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol 2007; 9: 2445-2456 [PMID: 17517063 DOI: 10.1111/j.1462-5822.2007.00972.x].
102. Maillard P, Walic M, Meuleman P, Roohvand F, Huby T, Le Goff W, Leroux-Roels G, Pécheur EI, Budkowska A. Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One 2011; 6: e26637 [PMID: 22039521 DOI: 10.1371/journal.pone.0026637].
103. Shimizu Y, Hishiki T, Sugiyama K, Ogawa K, Funami K, Kato A, Ohsaki Y, Fujimoto T, Takaku H, Shimotohno K. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV- Associated lipoproteins. Virology 2010; 407: 152-159 [PMID: 20822787 DOI: 10.1016/j.virol.2010.08.011].
104. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized lowdensity lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 2006; 43: 932-942 [PMID: 16628670 DOI: 10.1002/Hep.21139].
105. Westhaus S, Bankwitz D, Ernst S, Rohrmann K, Wappler I, Agné C, Luchtefeld M, Schieffer B, Sarrazin C, Manns MP, Pietschmann T, Ciesek S, von Hahn T. Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein. Hepatology 2013; 57: 1716-1724 [PMID: 23212706 DOI: 10.1002/hep.26190].
106. Lavie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 2006; 44: 1626-1634 [PMID: 17133472 DOI: 10.1002/Hep.21406].
107. Cai Z, Cai L, Jiang J, Chang KS, van der Westhuyzen DR, Luo G. Human serum amyloid A protein inhibits hepatitis C virus entry into cells. J Virol 2007; 81: 6128-6133 [PMID: 17329325 DOI: 10.1128/JVI.02627-06].
108. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005; 102: 4560-4565 [PMID: 15767578 DOI: 10.1073/pnas.0501275102].
109. Dreux M, Dao Thi VL, Fresquet J, Guérin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- And extra-cellular domains. PLoS Pathog 2009; 5: e1000310 [PMID: 19229312 DOI: 10.1371/journal.ppat.1000310].
110. Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 2014; 60: 1508-1518 [PMID: 24797654 DOI: 10.1002/hep.27196].
111. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2007; 81: 374-383 [PMID: 17050612 DOI: 10.1128/JVI.01134-06].
112. Dreux M, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, Pécheur EI, Cosset FL. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem 2007; 282: 32357-32369 [PMID: 17761674 DOI: 10.1074/jbc.M705358200].
113. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010; 84: 5751-5763 [PMID: 20357091 DOI: 10.1128/JVI.02200-09].
114. Brazzoli M, Bianchi A, Filippini S, Weiner A, Zhu Q, Pizza M, Crotta S. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 2008; 82: 8316-8329 [PMID: 18579606 DOI: 10.1128/JVI.00665-08].
115. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 2010; 51: 1144-1157 [PMID: 20069648 DOI: 10.1002/hep.23445].
116. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008; 82: 5007-5020 [PMID: 18337570 DOI: 10.1128/JVI.02286-07].
117. Rhainds D, Bourgeois P, Bourret G, Huard K, Falstrault L, Brissette L. Localization and regulation of SR-BI in membrane rafts of HepG2 cells. J Cell Sci 2004; 117: 3095-3105 [PMID: 15226391 DOI: 10.1242/jcs.01182].
118. Charrin S, Manié S, Thiele C, Billard M, Gerlier D, Boucheix C, Rubinstein E. A physical and functional link between cholesterol and tetraspanins. Eur J Immunol 2003; 33: 2479-2489 [PMID: 12938224 DOI: 10.1002/eji.200323884].
119. Cherukuri A, Shoham T, Sohn HW, Levy S, Brooks S, Carter R, Pierce SK. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling- Active lipid rafts. J Immunol 2004; 172: 370-380 [PMID: 14688345].
120. Harris HJ, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, Mee CJ, McCaffrey K, Young S, Drummer H, Balfe P, McKeating JA. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010; 285: 21092-21102 [PMID: 20375010 DOI: 10.1074/jbc.M110.104836].
121. Bertaux C, Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol 2006; 80: 4940-4948 [PMID: 16641285 DOI: 10.1128/JVI.80.10.4940-4948.2006].
122. Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand- Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cell Microbiol 2008; 10: 606-617 [PMID: 17979982 DOI: 10.1111/j.1462-5822.2007.01070.x].
123. Schwarz AK, Grove J, Hu K, Mee CJ, Balfe P, McKeating JA. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol 2009; 83: 12407-12414 [PMID: 19776133 DOI: 10.1128/JVI.01552-09].
124. Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, Schwarz A, Moreau M, Owen JS, Leroux- Roels G, Balfe P, McKeating JA. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 2007; 81: 3162-3169 [PMID: 17215280 DOI: 10.1128/JVI.02356-06].
125. Pichler H, Riezman H. Where sterols are required for endocytosis. Biochim Biophys Acta 2004; 1666: 51-61 [PMID: 15519308 DOI: 10.1016/j.bbamem.2004.05.011].
126. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80: 6964-6972 [PMID: 16809302 DOI: 10.1128/JVI.00024-06].
127. Lavillette D, Pécheur EI, Donot P, Fresquet J, Molle J, Corbau R, Dreux M, Penin F, Cosset FL. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 2007; 81: 8752-8765 [PMID: 17537855 DOI: 10.1128/JVI.02642-06].
128. Lavillette D, Bartosch B, Nourrisson D, Verney G, Cosset FL, Penin F, Pécheur EI. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem 2006; 281: 3909-3917 [PMID: 16356932 DOI: 10.1074/jbc.M509747200].
129. Haid S, Pietschmann T, Pécheur EI. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem 2009; 284: 17657-17667 [PMID: 19411248 DOI: 10.1074/jbc.M109.014647].
130. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645].
131. Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, Proll SC, McDermott JE, Gritsenko MA, Zhang Q, Zhao R, Metz TO, Camp DG, Waters KM, Smith RD, Rice CM, Katze MG. Temporal proteome and lipidome profiles reveal hepatitis C virus- Associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 2010; 6: e1000719 [PMID: 20062526 DOI: 10.1371/journal. ppat.1000719].
132. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006; 3: 321-331 [PMID: 16679290 DOI: 10.1016/j.cmet.2006.03.007].
133. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, Tsukuda T, Shimma N, Aoki Y, Arisawa M, Kohara M, Sudoh M. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 2005; 1: 333-337 [PMID: 16408072 DOI: 10.1038/nchembio742].
134. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci USA 2009; 106: 7577-7582 [PMID: 19376974 DOI: 10.1073/pnas.0902693106].
135. Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, Santarella-Mellwig R, Habermann A, Hoppe S, Kallis S, Walther P, Antony C, Krijnse-Locker J, Bartenschlager R. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 2012; 8: e1003056 [PMID: 23236278 DOI: 10.1371/journal.ppat.1003056].
136. Martin S, Parton RG. Lipid droplets: A unified view of a dynamic organelle. Nat Rev Mol Cell Biol 2006; 7: 373-378 [PMID: 16550215 DOI: 10.1038/nrm1912].
137. Moradpour D, Englert C, Wakita T, Wands JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996; 222: 51-63 [PMID: 8806487 DOI: 10.1006/viro.1996.0397].
138. Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 2006; 80: 2832-2841 [PMID: 16501092 DOI: 10.1128/JVI.80.6.2832-2841.2006].
139. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097 [PMID: 17721513 DOI: 10.1038/ncb1631].
140. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78 (Pt 7): 1527-1531 [PMID: 9225025].
141. Olofsson SO, Boström P, Andersson L, Rutberg M, Perman J, Borén J. Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta 2009; 1791: 448-458 [PMID: 18775796 DOI: 10.1016/j.bbalip.2008.08.001].
142. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104: 5848-5853 [PMID: 17376867 DOI: 10.1073/pnas.0700760104].
143. Thomssen R, Bonk S, Propfe C, Heermann KH, Köchel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992; 181: 293-300 [PMID: 1335546].
144. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82: 2120-2129 [PMID: 18077707 DOI: 10.1128/JVI.02053-07].
145. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 2008; 47: 1437-1445 [PMID: 18393287 DOI: 10.1002/hep.22197].
146. Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006; 80: 11074-11081 [PMID: 16956946 DOI: 10.1128/JVI.01150-06].
147. Tao W, Xu C, Ding Q, Li R, Xiang Y, Chung J, Zhong J. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 2009; 395: 67-76 [PMID: 19793603 DOI: 10.1016/j.virol.2009.09.006].
148. Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, Penin F, Lotteau V, André P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One 2009; 4: e4233 [PMID: 19156195 DOI: 10.1371/journal.pone.0004233].
149. Nourbakhsh M, Douglas DN, Pu CH, Lewis JT, Kawahara T, Lisboa LF, Wei E, Asthana S, Quiroga AD, Law LM, Chen C, Addison WR, Nelson R, Houghton M, Lehner R, Kneteman NM. Arylacetamide deacetylase: A novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. J Hepatol 2013; 59: 336-343 [PMID: 23542347 DOI: 10.1016/j.jhep.2013.03.022].
150. Fazio S, Linton MF, Swift LL. The cell biology and physiologic relevance of ApoE recycling. Trends Cardiovasc Med 2000; 10: 23-30 [PMID: 11150725].
151. Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007; 81: 13783-13793 [PMID: 17913825 DOI: 10.1128/JVI.01091-07].
152. Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 2009; 83: 12680-12691 [PMID: 19793818 DOI: 10.1128/JVI.01476-09].
153. Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 2011; 141: 1057-1066 [PMID: 21699799 DOI: 10.1053/j.gastro.2011.06.010].
154. Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wölk B, Kaderali L, Pietschmann T. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 2014; 88: 1433-1446 [PMID: 24173232 DOI: 10.1128/JVI.01815-13].
155. Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 2010; 51: 43-53 [PMID: 20014138 DOI: 10.1002/hep.23278].
156. Merz A, Long G, Hiet MS, Brügger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011; 286: 3018-3032 [PMID: 21056986 DOI: 10.1074/jbc.M110.175018].
157. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. J Virol 2008; 82: 9647-9656 [PMID: 18667498 DOI: 10.1128/JVI.00914-08].
158. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T. Critical role of virionassociated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 2008; 82: 5715-5724 [PMID: 18367533 DOI: 10.1128/JVI.02530-07].
159. Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, Wakita T, Suzuki T. Structural requirements of virion- Associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus. J Gen Virol 2011; 92: 2082-2087 [PMID: 21593275 DOI: 10.1099/vir.0.032391-0].
160. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82: 12020-12029 [PMID: 18829747 DOI: 10.1128/JVI.01569-08].
161. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 2011; 85: 2224-2234 [PMID: 21123377 DOI: 10.1128/JVI.01594-10].
162. Koutsoudakis G, Dragun J, Pérez-Del-Pulgar S, Coto-Llerena M, Mensa L, Crespo G, González P, Navasa M, Forns X. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. PLoS One 2012; 7: e52651 [PMID: 23300734 DOI: 10.1371/journal.pone.0052651].
163. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of betalipoproteins and immunoglobulins. Med Microbiol Immunol 1993; 182: 329-334 [PMID: 8121333].
164. Felmlee DJ, Fauvelle C, Heydmann L, Hiet MS, Fofana I, Bartenschlager R, Stoll-Keller F, Zeisel MB, Fafi-Kremer S, Baumert TF. Hepatitis C Virus Liver Transplantation Escape Variant Is Characterized by Both Enhanced Triglyceride- Rich Lipoprotein Association and Sensitivity to Apoe Antibodies. J Hepatol 2013; 58: S468-S468.
165. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010; 207: 2019-2031 [PMID: 20713596 DOI: 10.1084/jem.20090766].
166. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008; 82: 569-574 [PMID: 17942559 DOI: 10.1128/JVI.01443-07].
167. Tan YJ, Lim SP, Ng P, Goh PY, Lim SG, Tan YH, Hong W. CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. Virology 2003; 308: 250-269 [PMID: 12706076].
168. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008; 48: 1761-1768 [PMID: 19030166 DOI: 10.1002/hep.22547].
169. Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Słowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012; 57: 17-23 [PMID: 22414763 DOI: 10.1016/j.jhep.2012.02.018].